Reply  by van den Brand, M & Rensing, B
As surgical collaborators in this study, we think that it shows
that the most appropriate approach to patients with multivessel
disease is apparent from this and the previous report from the
ARTS trial. This could not have been expressed better than in the
last sentence in the Results section, which should have been moved
to the Conclusions section of the report.
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REPLY
We have read with interest the comments of Doctors Elami and
Merin relating to our study “The Effect of Completeness of
Revascularization on Event-free Survival” (1). It is remarkable that
the title of their communication is “Stented Angioplasty or
Coronary artery Bypass Graft Surgery for Multivessel Disease?”
Indeed, most of their comments apply to the general results of the
ARTS trial as published by Serruys et al. (2). The reasoning
behind our study was threefold. First, both angioplasty and surgery
have a substantial number of patients left with anatomical incom-
plete revascularization. This means that interventional cardiolo-
gists should seek optimal patient selection to achieve complete
revascularization, as this leads to a 7% higher event-free survival at
one year. Surgeons also could do better, as they achieve complete
revascularization in only five out of six patients, albeit without a
significant difference in outcome between both groups at one year.
Second, even with incomplete percutaneous revascularization,
the number of irreversible events was not higher than for the other
three subgroups, as can be learned from Table 3 of our report.
Thus, the higher number of revascularizations in the (PCI)
patients did not lead to a higher number of infarctions, although
left ventricular function has not routinely been measured at
follow-up. This means that within the selection criteria of the
ARTS trial, the patient and the doctor could opt for intentionally
incomplete percutaneous revascularization without endangering
the patient’s life expectancy and without infarcts and cerebrovas-
cular accidents. This still appeals to numerous patients as an
agreeable alternative to surgery, notwithstanding the advances that
have been made in surgical techniques. At one year, 98% of PCI
patients with complete revascularization were free from coronary
artery bypass graft surgery (CABG) compared to only 90% of the
incompletely percutaneously revascularized patients.
Third, in European countries the portion of PCI in the total
number of coronary revascularizations is between 40% and 70% (3).
Nevertheless, the vast majority ot these percutaneous revascu-
larizations are still performed in patients with single-vessel disease
(e.g., 86% in The Netherlands; database BHN, first quarter 2002).
The ARTS trial was developed to explore the outcome of
multivessel-stented PCI. In retrospect, we tried to investigate
whether incomplete and complete revascularization had the same
effect on percutaneously and surgically treated patients. We found
that patients incompletely revascularized with PCI needed more
reinterventions. To enhance the outcome of multivessel PCI, we
concluded that complete revascularization is a good guarantee for
survival without CABG, with a 13% re-PCI rate. If the promises
of rapamycin-coated stents are confirmed (4), and restenoses are
prevented, complete PCI revascularization can compete with
surgery, not only in preventing surgery, but also making it a
one-time procedure like surgery. But even without restenosis,
careful selection of patients to achieve complete revascularization is
a prerequisite for event-free survival after PCI.
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